Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TO-211
- Development stage
- Unknown
- Lead developer
- Torii Pharmaceutical
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Percutaneous
01
Overview
TO-211 is an allergen extract developed by Torii Pharmaceutical for the diagnosis of allergic diseases caused by the mold *Alternaria*. It is specifically designed for use in skin scratch or prick tests to identify sensitization to *Alternaria* allergens. The product functions by cross-linking allergen-specific Immunoglobulin E (IgE) antibodies on the surface of cutaneous mast cells, which triggers degranulation and the release of inflammatory mediators, resulting in a visible wheal-and-flare reaction. TO-211 is currently in Phase III clinical development in Japan, where studies are evaluating its diagnostic concordance with existing allergen extracts and specific IgE antibody testing in patients with *Alternaria*-induced allergic diseases.
- Other names
- Alternaria allergen extractAlternaria scratch test extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on TO-211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TO-211.